Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday

Costco beat fiscal Q4 expectations with EPS of $6.75 versus $6.52 consensus and revenue of $95.72B versus $94.86B, though shares rose only 0.2% after hours. Scholastic missed estimates with a $3.63-per-share loss versus an expected $3.40 loss and $216.8M of sales versus $224.7M forecast, sending shares down 12.2%. Prime Medicine gained 11.7% after FDA clearance of its IND for PM647, while INLIF surged 93.2% after reporting 26.01% first-half revenue growth to $12.94M.

Analysis

COST's modest after-hours reaction despite an earnings beat suggests the market is focused on valuation durability rather than the quarter. At roughly a premium multiple to large-cap retail peers, the investable question is whether membership-fee growth, renewal rates, and U.S. comparable-sales ex-fuel can sustain enough operating leverage to offset wage, shrink, and e-commerce fulfillment costs. Over the next 1-3 months, a muted post-print move creates a better entry only if management commentary supports accelerating membership income and stable gross-margin ex-gas; otherwise, COST remains vulnerable to multiple compression even on continued estimate beats.

SCHL's miss matters less for its absolute earnings power than for what it implies about the school purchasing cycle and consumer discretionary demand in children's publishing. A weak seasonal setup can force promotional activity and inventory actions, creating disproportionate EBIT pressure in a business with limited scale leverage. The likely near-term downside is concentrated in SCHL, but HMH is private and there is limited clean public read-through; this is not a broad education-services short signal.

PRME's regulatory clearance removes an early binary development hurdle but does not validate clinical efficacy, delivery, durability, or eventual commercial differentiation in gene editing. The initial move is therefore more likely to improve financing optionality than intrinsic value; watch cash runway and trial-enrollment timelines before underwriting upside. INLF's sharp move on lightly scrutinized interim results is primarily a liquidity and verification risk rather than a fundamental rerating until audited cash conversion, customer concentration, and exchange-compliance details are established.

Key Decisions for Investors

• COST: maintain a watchlist long rather than chase at the open; initiate only on a 3-5% pullback if U.S. comparable-sales ex-fuel, renewal rates, and membership-fee income support upward FY estimates. Use a 6-12 month horizon; thesis fails if traffic weakens or gross-margin guidance deteriorates, since the premium multiple leaves limited cushion.
• SCHL: consider a tactical 1-3 month short only if the regular-session decline remains materially below a 10% reset and management indicates weaker full-year sell-through or higher promotions. Cover on evidence of a stable back-to-school order book or maintained full-year EBIT expectations; position size should be modest given low liquidity and seasonal volatility.
• PRME: do not treat the clearance as a standalone long catalyst. Set an alert for financing terms, first-patient dosing, and initial safety data; a long is actionable only if runway extends beyond the next meaningful clinical readout without deeply dilutive issuance.
• INLF: avoid momentum exposure until audited financials confirm receivables collection and operating cash flow. For event-driven books, treat any inability to sustain post-open liquidity or disclosure of customer concentration as a short/watch catalyst, but do not establish a borrow-dependent position without confirmed availability.